Healio: Premenopausal bilateral oophorectomy linked to risk for chronic conditions in midlife Please provide your email address to receive an email when new articles are posted on . Premenopausal bilateral oophorectomy before age 46 years raised odds of arthritis, asthma, bone fractures and ... Healio: Increased prediabetes, undiagnosed diabetes in premenopausal women in past 2 decades The American Journal of Managed Care: Global Incidence of Premenopausal, Postmenopausal Breast Cancer Rising Higher-income countries are seeing their rates of premenopausal breast cancer increase faster, whereas cases of postmenopausal breast cancer are increasing in number faster in lower-income studies.
ascopubs.org: Adding Ovarian Suppression to Tamoxifen for Premenopausal Breast Cancer: A Randomized Phase III Trial Capivasertib Plus Paclitaxel Versus Placebo Plus Paclitaxel As First-Line Therapy for Metastatic Triple-Negative Breast Cancer: The PAKT Trial We enrolled 1,483 premenopausal women (age ≤ 45 years) ... Adding Ovarian Suppression to Tamoxifen for Premenopausal Breast Cancer: A Randomized Phase III Trial MedPage Today: Challenges in Adjuvant Therapy for Premenopausal Women Diagnosed With Luminal Breast Cancers Challenges in Adjuvant Therapy for Premenopausal Women Diagnosed With Luminal Breast Cancers ascopubs.org: Neoadjuvant Degarelix Versus Triptorelin in Premenopausal Patients Who Receive Letrozole for Locally Advanced Endocrine-Responsive Breast Cancer: A Randomized Phase II Trial Detection of Relapse by Tumor Markers Versus Imaging in Children and Adolescents With Nongerminomatous Malignant Germ Cell Tumors: A Report From the Children’s Oncology Group Premenopausal women with ... Neoadjuvant Degarelix Versus Triptorelin in Premenopausal Patients Who Receive Letrozole for Locally Advanced Endocrine-Responsive Breast Cancer: A Randomized Phase II Trial SEATTLE -- The monoclonal antibody romosozumab (Evenity) increased bone mineral density (BMD) in premenopausal women with idiopathic osteoporosis, according to a small, phase II open-label study. Business Wire: Level One Evidence Proves Premenopausal Patients within the Ultra-Low Subset of Agendia’s MammaPrint Low Risk Result Can Safely Forgo Chemotherapy Level One Evidence Proves Premenopausal Patients within the Ultra-Low Subset of Agendia’s MammaPrint Low Risk Result Can Safely Forgo Chemotherapy
